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Abstract
The field of psychology, as with many other disciplines, has been increasingly interested in being able to measure the
effectiveness of behavioral interventions. This trend has led to a number of different approaches for measuring clinical
significance, each addressing a slightly different aspect of the clinical outcome. Recently, clinical psychologists (and clients)
have supported the contention that one of the most important therapeutic questions is whether clients are functioning
equivalently to normal controls following an intervention. To address this question, Kendall, Marrs-Garcia, Nath, and
Sheldrick (1999) presented an approach to measuring clinical significance that utilizes tests of equivalence. The present
study clarifies the nature of the hypotheses being conducted in measuring clinical significance with tests of equivalence and
extends the approach by incorporating recent advances in equivalence testing. A revised approach for evaluating clinical
significance via equivalence testing is proposed, and an empirical example demonstrating this approach is provided.
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Kendall and Grove stated that ‘‘convincing demon-
strations of therapeutic efficacy must provide evi-
dence, where possible, that once troubled and
disordered clients are now, after treatment, not
distinguishable from a meaningful and representative
nondisturbed reference group’’ (1988, p. 148).
Further, Jacobsen and Revenstorf (1988) claimed
that clients ‘‘expect to be as normal as their
functioning counterparts by the time therapy has
ended’’ (p. 134). Kendall and many others (e.g.,
Jacobsen, Follette, & Revenstorf, 1984; Jacobson &
Truax, 1991) have also highlighted the inability of
traditional statistical methods, which compare
changes in response to the intervention across
treatment conditions, to address the question of
whether the treated individuals are equivalent to a
normal comparison group following the interven-
tion. This is also important in light of the fact that
for many clinical issues the level attained by the end
of therapy is considerably more predictive of long-
term functioning than the magnitude of change (e.g.,
Baucom & Mehlman, 1984). In the 1980s, Kendall
et al. (e.g., Kendall & Grove, 1988; Kendall &
Norton-Ford, 1982) discussed several methods that
attempted to assess the important question of
whether the treated and normal comparison popula-
tions are equivalent; however, Kendall faced several
statistical issues that limited the ability of the
procedures to directly answer this question. How-
ever, advances in the field of equivalence testing led
Kendall to develop the highly regarded normative
comparisons approach (Kendall, Marrs-Garcia,
Nath, & Sheldrick, 1999), which provided a method
for evaluating the equivalence of treated and normal
comparison groups. Not only did Kendall et al.’s
equivalence-based approach provide clinical re-
searchers with a fresh approach to the issue of
clinical significance, but it finally directly addressed
the question of whether the treated population was
equivalent to a normal comparison group.
An important distinction to make when discussing
clinical significance is between methods for evaluat-
ing group-level and individual-level clinical signifi-
cance. Group-level methods for evaluating clinical
significance address the question of whether the
intervention was effective across the entire treatment
group, whereas individual-level methods address the
effectiveness of an intervention separately for
each individual. In this study, we specifically deal
with methods for evaluating group-level clinical
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significance, which is not to say that methods for
evaluating individual-level clinical significance are
not important. In fact, methods for evaluating
individual-level clinical significance due to Jacobsen
et al. (e.g., Jacobsen & Truax, 1991) are the most
popular of all available methods for assessing clinical
significance (Ogles, Lunnen, & Bonesteel, 2001).
Further, these methods have been recommended
against alternatives in a review of several techniques
for assessing clinical significance (Bauer, Lambert, &
Nielsen, 2004) and can be very effective at calculat-
ing the proportion of individuals who are recovered,
unchanged, and so on. However, we tend to favor
group-level methods for evaluating clinical signifi-
cance because clinicians, and clinical researchers, are
often interested in knowing globally whether an
intervention is effective, and this question, in our
opinion, is better addressed at the group level.
The purpose of the current study is to review the
equivalence-based method for assessing group-level
clinical significance proposed by Kendall et al.
(1999), and extend the method by addressing some
of the issues that were raised by Kendall et al. in the
original study. Specifically, our goals are to (a) clarify
the logic behind conducting only one of the two one-
sided t tests when conducting the test of equivalence
and provide a simple solution to this issue; (b)
continue the discussion by Kendall et al. on selecting
an appropriate equivalence interval and offer a
recommendation that is based on utilizing multiple
equivalence intervals; (c) address the important
issues (raised by Kendall et al.) of sample size and
variance heterogeneity across the treated and normal
comparison samples by recommending a heterosce-
dastic test of equivalence; and (d) discuss whether
the third and fourth steps of Kendall’s method (i.e.,
implementing a traditional test of the difference
between the means of the treated and normal
comparison groups and comparing those results
with those of the equivalence test) are necessary.
We end by presenting an applied example that
demonstrates the incorporation of the suggestions
offered here. The goal is to be able to provide clinical
researchers with a meaningful, logical, and easy-to-
implement approach to evaluating the clinical sig-
nificance of an intervention.
Kendall’s Equivalence-Based Approach to
Clinical Significance
Kendall et al. (1999) raise two important questions
that are at the heart of evaluating clinical signifi-
cance: (a) Are the treated individuals no longer
affected by their initial condition? (b) Are the treated
individuals distinguishable from a normative sample
of individuals on relevant measures of the condition?
The second question directly addresses the issue of
whether the group of treated individuals is equiva-
lent to the group of normal control individuals. It is
important to point out that in some cases this
question is not a realistic goal of the intervention.
For example, Kazdin (2001) states that autism is an
example of a disorder with behaviors that are
extremely difficult to change and, therefore, equiva-
lence-based methods of demonstrating clinical sig-
nificance are inappropriate. Wise (2004) also
describes dual-diagnosis disorders (especially those
including medical problems) as an example of a case
where improvement to normal may be unrealistic.
However, for clinical issues where full (or close to
full) recovery is attainable, Kendall et al. suggest that
clinical researchers evaluate the second question
directly by determining whether the treated and
normal comparison populations are equivalent using
the two-independent-samples test of equivalence
proposed by Schuirmann (1987). The normal com-
parison population would be selected to be as
representative of the clinical population as possible,
except without having any clinical diagnoses. Popu-
lation samples may be appropriate in many situa-
tions, although in some (i.e., when the clinical
sample is distinctly different from the population
sample on certain characteristics) it is recommended
that the researcher collect normative data from a
more representative sample. A researcher would
declare the treated and normal comparison groups
(mt and mn, respectively) equivalent if Ho1: mt  mnd
and Ho2: mt  mnB-d are both rejected. d represents
the critical mean difference for declaring the two
population means equivalent; in other words, any
mean difference smaller than d would be considered
meaningless within the framework of the experi-
ment. Ho1 is rejected if t15ta,df where:
t1
(M1 M2) dffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
(n1  n2)[(n1  1)s
2
1  (n2  1)s
2
2]
n1n2 (n1  n2  2)
s
and Ho2 is rejected if t2]ta,df where:
t2
(M1 M2) (d)ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
(n1  n2)[(n1  1)s
2
1  (n2  1)s
2
2]
n1n2 (n1  n2  2)
s :
M1 and M2 are the group means, n1 and n2 are the
group sample sizes, s1 and s2 are the group standard
deviations, and ta,df is the upper tailed a-level t
critical value with n1n2  2 degrees of freedom.
As discussed in detail by Cribbie, Gruman, and
Arpin-Cribbie (2004), an important consideration
with any test of equivalence is the power of the test
statistics. For example, with a traditional indepen-
dent-samples t test, power for detecting differences
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between the means increases as sample sizes increase
(assuming all other factors are held constant).
However, when a test of equivalence is used to
explore whether two groups are equivalent, in-
creased sample sizes no longer increase power for
detecting differences but instead increase power for
detecting equivalence. The overall power of the
equivalence test is a function of the critical mean
difference, sample size, difference between the
means of the groups, variability within the groups,
and Type I error rate; power increases with a larger
critical mean difference, larger sample sizes, smaller
differences between the means, less variability within
the groups, and a larger Type I error rate. For a more
thorough discussion of the power of equivalence
tests under several different conditions, see Cribbie
et al. (2004).
Extending Kendall’s Approach
One t Test or Two?
Kendall et al. (1999) state that ‘‘if the range is
symmetrical (jd1jd2) around zero, then the two
t tests are identical; therefore, only one test needs to
be conducted’’ (p. 287). This point is emphasized in
Sheldrick, Kendall, and Heimberg (2001), where
only one of the prior t tests (t1, t2) is used in an
empirical example because ‘‘the specified range of
closeness in this case is symmetrical about the
normative mean’’ (p. 427). It is important to clarify
that, with the two-independent-groups equivalence
test due to Schuirmann (the procedure that Kendall
et al. describe is originally due to Schuirmann, 1987,
although they reference a more recent article,
Rogers, Howard, & Vessey, 1993, that outlines the
test due to Schuirmann), both t tests must be
statistically significant in order to declare the groups
equivalent. In other words, rejection of Ho1 implies
that m1  m2Bd, and rejection of Ho2 implies that m1 
m2d. Rejection of both hypotheses implies that
m1  m2 falls within the bounds of (d, d) and the
means are deemed equivalent.
It is important to point out here that Kendall et al.
use the terms d1 and d2 to represent d and d. From
the prior formulas, it should be evident why both
tests need to be conducted, because t1 will only equal
t2 if M1M2 (which would have near zero prob-
ability). Kendall et al. (1999) also note that ‘‘if the
range is asymmetrical (jd1j"d2), then only the more
stringent t-test corresponding to the smaller delta
value needs to be conducted. If this test is signifi-
cant, then the other must be as well’’ (p. 287). Again,
in this situation, it is important to clarify that both
tests would need to be conducted. For example,
imagine that d1 is set at 20 and d2 is set at 10.
Which test is most stringent will depend on M1 M2.
If M1  M218, then the test associated with d1
will be most stringent, whereas if M1 M218, then
the test associated with d2 will be most stringent.
The only exception to this rule, which Kendall et al.
experienced in their applied examples, occurs when
d2 is set equal to infinity (). In this situation, only
one test can be conducted because t1 is undefined
with  in the equation. Streiner (2003) describes
the approach of one-tailed equivalence testing (i.e.,
setting one of the equivalence limits to , which is
often referred to as noninferiority testing) and
explains how it is valuable when the goal is to
demonstrate that a new therapy is no worse than
the standard therapy. However, we do not recom-
mend this strategy (i.e., setting one of the limits to
) when evaluating clinical significance because this
negates the possibility of finding that the clinical
group is not equivalent to the normative group at
posttest because they are actually scoring better than
the normative group. Although this situation will be
rare, and it should be probed extensively to deter-
mine the cause, it could highlight situations in which
the therapy specifically addresses issues that are
probed on the measuring instruments (e.g., ques-
tionnaires) and the treated group may show artifi-
cially inflated improvements. To summarize, unless
one of the equivalence bounds are set to , which
we do not recommend for completeness, both t tests
should be conducted to establish the equivalence of
the treatment and normative conditions.
Establishing an Equivalence Interval
The first step in conducting Schuirmann’s test of
equivalence is to establish a critical mean difference
for declaring two population means equivalent (d).
Rogers et al. (1993) stated that ‘‘any difference small
enough to fall within that equivalence interval would
be considered clinically and/or practically unimpor-
tant’’ (p. 553). Within the framework of clinical
significance testing, setting d amounts to establishing
what difference between the treated and normative
groups at posttest would be clinically meaningless
(Cribbie et al., 2004).
The selection of d is an important aspect of
equivalence testing that is primarily dependent on
a subjective ‘‘level of confidence’’ with which to
declare two (or more) populations equivalent. This
level of confidence can take on many different forms,
including a raw value (e.g., mean test scores different
than 10 points), a percentage difference (e.g.,9
10%), a percentage of the pooled standard deviation
difference, and so on. As d increases, the probability
of declaring the groups equivalent increases,
but greater (and potentially important) differences
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between the groups are considered meaningless. On
the other hand, smaller values of d make it harder to
establish equivalence, although there is more con-
fidence that differences between groups declared
equivalent are clinically insignificant. In the applied
examples of Kendall et al. (1999) and Sheldrick
et al. (2001), they utilized an equivalence interval of
1 SD unit (calculated using the normative group
data). As in Kendall’s examples, it is most common
in equivalence testing to utilize a single value of d;
however, we find this strategy uninformative in
equivalence-based clinical significance testing be-
cause there are clearly different degrees of ‘‘close-
ness’’ between the treated and normative groups. In
other words, using a single value of d does not allow
the researcher to quantify the level of closeness
established by the therapy (unless equivalence was
established with the smallest practical value of d or
nonequivalence was concluded with the largest
practical value of d).
We recommend that researchers assessing the
equivalence of treated and normative groups, assum-
ing that returning the clinical population to normal
functioning is a realistic goal of the intervention,
utilize the following levels of d: (a) definitive
equivalence, d.5 (snormal); (b) probable equiva-
lence, dsnormal; and (c) potential equivalence, d
1.5 (snormal), where snormal is the standard deviation
of the normal comparison group scores. It is
important to highlight that, although these values
provide a general framework for qualifying equiva-
lence, researchers are encouraged to consider alter-
native quantifications/qualifications of d that may be
more appropriate for their specific studies. For
example, establishing equivalence with d1.5 may
have a completely different meaning in a population
that is difficult to return to normal functioning than
in a population where returning to normal function-
ing is a realistic goal of the intervention. Applications
of these values of d are presented in the examples
presented later.
The Problem of Sample Size and Variance
Heterogeneity
Kendall et al. (1999) identified a serious issue with
evaluating the equivalence of treated and normal
comparison groups with Schuirmann’s (1987) ap-
proach, namely that the sample sizes and variances
of the groups are regularly different. Boneau (1960),
Kohr and Games (1974), and many others since
have identified that the independent-samples t test is
not accurate when sample sizes and variances are
unequal. More specifically, Boneau found that
empirical Type I error rates (when a.05) could
be as large as .16 or as small as .01 when sample sizes
and variances are unequal, but that rates for the
independent-samples Welch t test were maintained
at approximately a even when sample sizes and
variances were extremely disparate. The direction
of the bias affecting the independent-samples t test
depends on the pattern of unequal sample sizes and
variances. If the larger sample size is paired with the
larger variance (and hence the smaller sample size is
paired with the smaller variance), then the test will
be conservative and it will be difficult to reject Ho1
and Ho2 (i.e., power is deflated). If the larger sample
size is paired with the smaller variance (and hence
the smaller sample size is paired with the larger
variance), then the test will be liberal and the
probability of committing a Type I error will exceed
a. Boneau, Kohr and Games, and others have also
shown that there is only a very slight advantage for
the original two-independent-samples t test over the
Welch test when sample sizes and variances are
equal.
Because Schuirmann’s test of equivalence is based
on the independent-samples t test, the sample size
and variance inequality issues that affect the inde-
pendent-samples t test also affect Schuirmann’s
equivalence test. Gruman, Cribbie, and Arpin-Crib-
bie (2007) demonstrated that empirical Type I error
rates for Schuirmann’s test of equivalence deviate
substantially from the nominal a level when sample
sizes and variances are unequal. Gruman et al. also
presented a heteroscedastic procedure for testing the
equivalence of two independent groups that draws
on the heteroscedastic standard error and degrees of
freedom due to Welch (1938) and Satterthwaite
(1946). For the SchuirmannWelch test of equiva-
lence, H01 is rejected if tW15ta,dfw and H02 is
rejected if tW2]ta,dfw where:
tW1
(M1 M2) dffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
s21
n1

s22
n2
s ;
tW2
(M1 M2) (d)ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
s21
n1

s22
n2
s ;
and
dfw

s21
n1

s22
n2
2
s41
n2
1
(n1  1)

s42
n2
2
(n2  1)
:
Type I error rates for the SchuirmannWelch test are
maintained at approximately a even when sample
sizes and variances are extremely unequal (Gruman
et al.). Further, there is very little power lost by using
the SchuirmannWelch procedure, instead of the
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original Schuirmann equivalence testing procedure,
when sample sizes and variances are equal. There-
fore, given that sample sizes and variances are often
unequal across treated and normal comparison
groups, and that there is very little power lost by
the Schuirmann procedure when sample sizes and
variances are equal, we recommend that researchers
evaluating clinical significance via equivalence test-
ing routinely utilize the SchuirmannWelch proce-
dure described previously.
A related issue is what effect nonnormal distribu-
tions will have on the Schuirmann and Schuirmann
Welch tests of equivalence. Although a full treatment
of this topic is beyond the scope of this article,
previous evidence has indicated that the modified
Welch statistics have reasonable Type I error rates
when distributions are slightly to moderately skewed
and sample sizes and variances are unequal (e.g.,
Algina, Oshima, & Lin, 1994). However, when
distributions become very asymmetric, Welch statis-
tics no longer produce accurate Type I error rates
when sample sizes and variances are unequal.
Instead, researchers should look to trimmed means
or rank-based solutions (e.g., Yuen, 1974; Zimmer-
man & Zumbo, 1989).
Should a Test of Differences Be Done on the
Posttest Means?
The final two steps of Kendall et al.’s (1999)
procedure for assessing clinical significance with
equivalence testing require that researchers conduct
a traditional two-independent-samples t test to
determine whether posttest mean differences exist
between the treated and normal comparison groups
and further to compare the results of this test with
those of the equivalence test. In our opinion, this
step is inconsistent with the research question being
addressed, namely whether or not the groups are
equivalent. In other words, because the null hypoth-
esis being evaluated by a two-independent-samples t
test is that the population means are exactly equal
(i.e., Ho: m1m2), with a large enough sample size
(and recall from the discussion by Achenbach, 2001,
that the normative samples can often be very large),
there will always be significant differences between
the treated and normal comparison groups, regard-
less of how small the mean differences are. But what
does this tell us? Our interest is in whether the
differences in the posttest means of the treated and
normal comparison groups fall within the established
equivalence interval (i.e., d to d), not whether
there are any, potentially trivial, differences between
the group means. We should point out here that with
a large enough sample size the power of the
equivalence test will also approach 1; however, the
fact that equivalence is being evaluated within an
interval makes the hypothesis more meaningful. To
summarize, we see no reason to conduct a traditional
test of mean differences on the posttest means.
However, we do see a lot of value in conducting a
traditional test of mean differences between the
pretest mean of the treated group and the normal
comparison group mean. In other words, if the
clinical (i.e., group to be treated) and the normal
comparison groups are not different at baseline
(assuming ample statistical power), then testing to
determine whether the groups are equivalent at
posttest is likely unnecessary. (It is also possible to
compare the pretest or posttest scores of the control
group with those of the normal comparison group
using a traditional test of mean difference, which
would contribute information about the status of the
control group, although this is not central to the
approach discussed here, which focuses on the status
of the treated population.) It is important to make it
clear that the reason for conducting a traditional test
of mean difference (as opposed to an equivalence
test) is that the research question is whether the
groups differ, not whether they are equivalent. It
should also be clear that it would not be recom-
mended that researchers utilize a standard two-
independent-samples t test given that sample sizes
and variances, as for the equivalence procedure, will
likely be unequal. Therefore, we recommend the
Welch (1938) heteroscedastic procedure that is
routinely reported in most software packages and
discussed earlier in this report.
Recommended Procedure for Evaluating
Clinical Significance Via Equivalence Testing
From the previous discussion, we recommend the
following steps in assessing whether the means of a
treated and a normal comparison group are equivalent:
Step 1: Compare the means of the pretest clinical
group (i.e., group to receive the intervention) and
the normal comparison group with a two-inde-
pendent-samples Welch t test. If this test is
statistically significant, continue to Step 2. If this
test is not statistically significant, then there is no
difference between the pretest clinical and normal
comparison groups; thus, evaluating the equiva-
lence of these groups at posttest is not meaningful.
Step 2a: Determine whether the posttest treated
group mean is equivalent to the normal compar-
ison group mean using an equivalence interval of
d.5 (snormal), where again snormal is the standard
deviation of the normal comparison group scores.
If this test is statistically significant, definitive
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equivalence has been established. If this test is not
statistically significant, continue to Step 2b.
Step 2b: Determine whether the posttest treated
group mean is equivalent to the normal compar-
ison group mean using an equivalence interval of
dsnormal. If this test is statistically significant,
probable equivalence has been established. If this
test is not statistically significant, continue to Step
2c.
Step 2c: Determine whether the posttest treated
group mean is equivalent to the normal compar-
ison group mean using an equivalence interval of
d1.5 (snormal). If this test is statistically signifi-
cant, potential equivalence has been established. If
this test is not statistically significant, equivalence
of the treated and normal comparison groups
cannot be established.
Note that it is possible that equivalence may not
have been established at Steps 2a, 2b, or 2c because
the treated group is actually performing better than
the normal comparison group at posttest. Although
this may seem like a best case scenario, this outcome
should also be cause for investigating whether some
aspect of the intervention resulted in the clinical
group responding in a biased manner on the posttest
measures. For example, if the intervention focused
specifically on material covered in the outcome
measures, then the treated group, although demon-
strating significant therapeutic change on the specific
outcome measures utilized, may not demonstrate
such extreme improvement on other measures of
posttest performance. An anonymous reviewer also
highlights that ‘‘teaching to the test’’ is one of several
potential threats to the validity of any intervention
study that should always be considered when inter-
preting the results of psychotherapy studies.
Empirical Example
Arpin-Cribbie, Irvine, and Ritvo (2009) conducted a
randomized clinical trial to evaluate the effectiveness
of a 10-week online cognitivebehavioral therapy
(CBT) for perfectionism. The CBT for perfection-
ism included topics related to accepting reality,
examining and reevaluating expectations, recogniz-
ing how certain ways of thinking cause distress,
dealing with negative moods, keeping perspective on
desires, and dealing with academic and performance
anxiety. Using a sample of undergraduate students
demonstrating extreme levels of perfectionism,
Arpin-Cribbie et al. randomly assigned subjects to
receive either the perfectionism-based CBT or no
intervention (control). The authors found that the
group receiving the perfectionism-based CBT im-
proved significantly more than the control group,
which received no intervention, on several measures
of perfectionism. Specifically, the group receiving
CBT improved significantly more than the control
group on the (a) Perfectionism Cognitions Inventory
(PCI; Flett, Hewitt, Blankstein, & Gray, 1998); (b)
Concern for Mistakes subscale of the Frost Multi-
dimensional Perfectionism Scale (MPSF-CM; Frost,
Marten, Lahart, & Rosenblate, 1990); (c) Self
Oriented Perfectionism subscale of the Hewitt and
Flett Multidimensional Perfectionism Scale (HF-
SOP; Hewitt & Flett, 1991); and (d) Socially
Prescribed Perfectionism subscale of the Hewitt
and Flett Multidimensional Perfectionism Scale
(HF-SPP; Hewitt & Flett, 1991). The means and
standard deviations for the CBT group, control
group, and normal comparison group are presented
in Table I. The normal comparison group data (N
107) was collected from a sample that was expected
to be very similar to the clinical group (i.e., the
group that demonstrated elevated perfectionism
levels, n77); specifically, the normal comparison
group was composed of undergraduate students who
were at the same academic level as the clinical group,
and the data were collected at same time of year as
the posttest clinical group data.
An important consideration in evaluating the
effectiveness of this therapy is whether the results
are clinically significant. In other words, within the
framework of Kendall et al.’s (1999) approach for
evaluating clinical significance through equivalence
testing, an important question is whether the CBT
group is equivalent to the normal comparison group
at posttest. To evaluate this question, we utilized the
equivalence testing-based approach to assessing
group clinical significance described previously,
and the results are presented in Table II. The results
indicate that the normal comparison group was
statistically different from the CBT group at pretest
on all measures of perfectionism. As indicated, this is
an important step because if the groups are not
different at pretest, then the need for an intervention
(or evaluating the equivalence of the groups at
posttest) is suspect. The results also indicate that
the posttest CBT mean was found to be equivalent
to the normal comparison group mean on all
perfectionism measures, with the groups being
declared definitively equivalent on the MPSF-CM
and HF-SPP, and probable equivalence was declared
for the PCI and HF-SOP. Appendix A provides
detailed information on steps for assessing equiva-
lence for the PCI measure.
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Discussion
It is now widely recognized that statistical tests for
demonstrating that an experimental group has im-
proved significantly more than a control group in a
randomized clinical trial fall short of addressing the
issue of clinical significance. Further, as psychology
and other disciplines increasingly value evidence-
based therapeutic methods (e.g., Kendall, 1997), it
will be very important that valid methods for
evaluating clinical significance are available to clin-
ical researchers. Advances in statistical methods for
assessing group equivalence (e.g., Schuirmann,
1987) provided the groundwork for Kendall et al.’s
(1999) normative comparison-based method for
assessing clinical significance, which has become
the premier method for assessing group-level clinical
significance. In this study, we extend the method
proposed by Kendall et al. by clarifying the nature of
the null hypotheses being conducted in each step of
the process and incorporating recent advances in
statistical methods for assessing equivalence (e.g.,
Gruman et al., 2007).
It is important to highlight that, although this
study has addressed many of the issues surrounding
the application of equivalence-based normal com-
parison tests in clinical interventions, there are other
important issues that require attention. For example,
we briefly introduce the idea that more advanced
methods may be required when distributions are
extremely nonnormal or when distribution shapes
differ across groups. Solutions to these problems,
including trimmed means and rank-based methods,
may be useful, but more research is necessary before
definitive recommendations can be made.
Another important issue, raised by an anonymous
reviewer of the current study, is that of nonindepen-
dence. More specifically, in many clinical studies,
the clients receiving treatment are nested within the
different participating therapists. It is expected that
the data analytic strategy that is used to assess
whether there is significant improvement in the
individuals following the intervention (usually in
relation to a control group) would control for any
nesting that occurs when multiple therapists are used
(e.g., a hierarchical linear modeling program) and
further that ample statistical power is available
(which becomes increasingly important in hierarch-
ical designs where it is necessary to ensure that there
are enough subjects within each cluster, e.g., thera-
pist). Moreover, an important question that arises is
whether normative comparison-based tests, such as
those discussed here, should be adjusted for the
nested nature of the design. There are two ways to
Table I. Means and Standard Deviations for Each Group on Each
of the Perfectionism Measures
Group PCI MPSF-CM HF-SOP HF-SPP
Normal control 47.37 24.87 66.80 55.56
(16.76) (7.04) (14.59) (11.57)
Treatment: CBT
Pre 66.14 29.43 85.49 64.83
(15.55) (6.94) (9.62) (13.87)
Post 50.24 23.34 73.20 55.52
(15.72) (5.02) (10.98) (10.84)
Treatment: control
Pre 69.75 30.21 84.37 65.92
(12.50) (7.87) (12.15) (13.52)
Post 70.36 30.23 85.17 67.76
(12.35) (8.59) (14.53) (13.25)
Note. PCIPerfectionism Cognitions Inventory; MPSF-CM
Frost Multidimensional Perfectionism Scale, Concern for Mis-
takes subscale; HF-SOPHewitt and Flett Multidimensional
Perfectionism Scale, Self-Oriented Perfectionism subscale; HF-
SPPHewitt and Flett Multidimensional Perfectionism Scale,
Socially-Prescribed Perfectionism subscale; CBTcognitive
behavioral therapy; Controlno intervention.
Table II. Normative Comparisons for Each of the Perfectionism Measures in the Arpin-Cribbie et al. Study
Stage of testing PCI MPSF-CM HF-SOP HF-SPP
Step 1: normal control group and
pretest treatment group different?
Yes (pB.001) Yes (pB.001) Yes (pB.001) Yes (pB.001)
Decision: Go to Step 2 Go to Step 2 Go to Step 2 Go to Step 2
Step 2: normal control group and posttest
treatment CBT group equivalent?
EI 0.5 (snormal) No (p1.053; Yes (p1.045; No (p1.359; Yes (p1.008;
p2B.001) p2B.001) p2B.001) p1.007)
EIsnormal Yes (p1B.001; NA Yes (p1B.001; NA
p2B.001) p2B.001)
EI1.5 (snormal) NA NA NA NA
Note. PCIPerfectionism Cognitions Inventory; MPSF-CMFrost Multidimensional Perfectionism Scale, Concern for Mistakes
subscale; HF-SOPHewitt and Flett Multidimensional Perfectionism Scale, Self-Oriented Perfectionism subscale; HF-SPPHewitt
and Flett Multidimensional Perfectionism Scale, Socially-Prescribed Perfectionism subscale; CBTcognitivebehavioral therapy; EI
equivalence interval; snormalstandard deviation of the normal control group on the variable of interest; NAnot applicable because
equivalence was declared at a smaller equivalence interval.
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address this question. One is to recognize that the
normative comparisons are being conducted post
hoc and, therefore, any potential nesting during the
intervention is irrelevant to tests being conducted
following the intervention. In this manner, the
question being asked is whether treated subjects
(regardless of which therapist they were assigned to
during the intervention) are equivalent to a group of
normal comparison subjects following the interven-
tion. The second way to address the problem, which
would be most appropriate if significant therapist-
level effects were identified, would be to take into
account these effects when conducting the normative
comparisons. A simple method for controlling for
the different effects of the therapists would be to
investigate normative comparison tests separately
within each therapist, or in other words compare
treated subjects from each therapist separately with
the normal comparison group. The disadvantage of
this approach would be that the sample sizes within
each therapist may be small and would limit the
power of the normative comparison tests. A second
approach would be to use posttest means (and
standard errors) that are adjusted for therapist-level
effects. The adjusted means could be obtained from
a hierarchical modeling program that allowed for the
nesting of subjects within therapists.
The revised approach that we recommend here is
intended to provide clinical researchers with a
method for specifically addressing the question of
whether clients are functioning equivalently to nor-
mal controls at the end of the therapeutic process.
This does not mean that we are recommending that
other potential statistical approaches (e.g., compar-
ing prepost changes between treated and control
groups, evaluating clinical significance at the indivi-
dual level) are abandoned, but only that these tests
provide a very important and unique method for
addressing clinical significance that can be used in
conjunction with these other statistical methods. In
other words, normative comparison-based tests of
clinical significance should be used in conjunction
with statistical tests of the change in outcomes from
pretest to posttest (that are preferably relative to a
control group and that also incorporate any nested
structures to the data) and individual-level tests of
clinical significance (e.g., Jacobsen & Truax, 1991).
As was discussed early in this article, equivalence-
based normal comparison methods provide the most
direct attempt to answer the question of whether the
treated group is equivalent to a normally functioning
control group. It is important to point out again that,
although it is appropriate to expect clients with many
clinical issues/disorders to have a full (or near full)
recovery (i.e., return to normal functioning) during
therapy, for many issues or disorders (e.g., autism) it
is not realistic to expect clients to return to normal
functioning during therapy. Further, as an anon-
ymous reviewer of this article pointed out, even the
best designed clinical trials experience nontrivial
numbers of participants who fail to respond to the
intervention. These nonresponsive individuals, in
addition to increasing the variability of posttest
scores (and, therefore, reducing the power of nor-
mative comparison tests), more importantly high-
light the importance of looking at individual-level
measures of clinical significance as a way of identify-
ing which (and possibly why) specific individuals did
not respond to the intervention.
We hope that the revised method for conducting
normal comparison-based assessments of clinical
significance is logical, easy to conduct, and clinically
meaningful. To make the procedure more widely
available, anyone interested in receiving an R pro-
gram (a free statistical software program available at
http://www.r-project.org) for conducting the ap-
proach outlined here can contact the authors.
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Appendix A: Calculations for Determining
Whether the CBT Group Is Equivalent to a
Normal Comparison Group on PCI Scores
Using Data from Arpin-Cribbie et al. (2009)
Step 1: Determine whether the mean of the CBT group at
pretest is statistically different from the normal compar-
ison group.
Ho: mCBTmNC
tw
X CBT  X NCffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
s2CBT
nCBT

s2NC
nNC
s  66:14 47:37ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
15:552
29

16:762
107
s 6:02
dfw

s2CBT
nCBT

s2NC
nNC
2
s4CBT
n2CBT (nCBT  1)

s4NC
n2NC (nNC  1)


15:552
29

16:762
107
2
15:554
292 (29 1)

16:764
1072 (107 1)
47:27:
Thus, because tw (6.02)tw, a.05, df47.27 (1.67),
we reject Ho: mCBTmNC and continue to Step 2.
Step 2a: Determine whether the postttest mean of the
CBT group is equivalent to the normal comparison group
with d.5 (snormal).
d.5 (snormal).5 (16.76)8.38
Ho1: mCBT  mNC8.38; Ho2: mCBT  mNCB8.38
tW1
(X CBT  X NC) dffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
s2CBT
nCBT

s2NC
nNC
s

(50:24 47:37) 8:38ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
15:722
29

16:762
107
s 1:65
tW2
(X CBT  X NC) (d)ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
s2CBT
nCBT

s2NC
nNC
s

(50:24 47:37) (8:38)ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
15:722
29

16:762
107
s 3:37
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dfw

s2CBT
nCBT

s2NC
nNC
2
s4CBT
n2CBT (nCBT  1)

s4NC
n2NC (nNC  1)


15:722
29

16:762
107
2
15:724
292 (29 1)

16:764
1072 (107 1)
 46:73:
Therefore, because tW2 (3.37)tw, a.05, df
46.73 (1.68), but tW1 (1.65)tw, a.05, df
46.73 (1.68), we do not reject Ho1: mCBT  mNC
8.38 and, therefore, conclude that the groups are not
equivalent (and continue to Step 2b).
Step 2b: Determine whether the postttest mean of the
CBT group is equivalent to the normal comparisons
group with dsnormal.
dsnormal16.76
Ho1: mCBT  mNC16.76; Ho2: mCBT  mNCB
16.76
tW1 
(XCBT  XNC) dffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
s2CBT
nCBT

s2NC
nNC
s

(50:24 47:37) 16:76ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
15:722
29

16:762
107
s 4:16
tW2 
(XCBT  XNC) (d)ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
s2CBT
nCBT

s2NC
nNC
s

(50:24 47:37) (16:76)ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
15:722
29

16:762
107
s  5:88
dfw 

s2CBT
nCBT

s2NC
nNC
2
s4CBT
n2CBT (nCBT  1)

s4NC
n2NC (nNC  1)


15:722
29

16:762
107
2
15:724
292 (29 1)

16:764
1072 (107 1)
 46:73:
Therefore, because tW1 (4.16)Btw, a.05, df46.73
(1.68) and tW2 (5.88)tw, a.05, df46.73 (1.68), we
reject Ho1: mCBT  mNCB16.76 and Ho2: mCBT 
mNCB16.76 and conclude that the groups are
equivalent at dsnormal16.76 (which is labeled
‘‘probable equivalence’’). At this point, Step 2c is
unnecessary because equivalence has been established
within a smaller interval than would be evaluated at
Step 2c, that is, 1.5 (snormal).
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